Blog

What a Government shutdown means for the USPTO?

By: Andreas Baltatzis, Esq.  |   January 19, 2018

In brief, full operations will continue based on sufficient reserve funds. Following that time, the USPTO will continue processing new patent and trademark applications, but limit most other operations.

CAFC Says Insubstantial Differences the Test for Chemical DOE

By: Andreas Baltatzis  |   May 26, 2017

The CAFC expressly endorses the “substantial differences” test for applying the doctrine of equivalents to chemical patents, bringing clarity to "sparse and confusing case law."

Leaders and Trends in Intellectual Property: Probiotics

By: Andreas Baltatzis and Gideon B. Eckhouse  |   March 21, 2017

Successful health and nutrition companies are built on innovative products and great brands. The strongest foundation for this is intellectual property, specifically patents and trademarks. Patents protect inventions and trademarks protect brands. We discuss IP trends and highlight companies leading the creation of new products and brands in probiotics. 

Leaders and Trends in Intellectual Property: Joint Health Products

By: Andreas Baltatzis & Gideon Eckhouse  |   February 10, 2017

Successful health and nutrition companies are built on innovative products and great brands. The strongest foundation for new products and brands is intellectual property, specifically patents and trademarks. Patents protect inventions and trademarks protect brands. 

FDA Approves Amgen’s Amjevita

By: Sandy King  |   September 27, 2016

On Friday, September 23, 2016, the U.S. Food and Drug Administration approved Amgen Inc.’s Amjevita, which is the biosimilar equivalent of AbbVie Inc.’s immunosuppressant Humira. The drug is approved for more than a half-dozen conditions listed on the branded drug’s label, including severe psoriasis and Crohn’s disease.

Pages